These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26974336)

  • 41. A Liver Index and its Relationship to Indices of HCC Aggressiveness.
    Carr BI; Guerra V; Giannini EG; Farinati F; Ciccarese F; Rapaccini GL; Di Marco M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Masotto A; Trevisani F
    J Integr Oncol; 2016 Oct; 5(4):. PubMed ID: 28580457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Significance of increased serum GGTP levels in HCC patients.
    Carr BI; Pancoska P; Branch RA
    Hepatogastroenterology; 2010; 57(101):869-74. PubMed ID: 21033244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers.
    Toyoda H; Kumada T; Osaki Y; Oka H; Urano F; Kudo M; Matsunaga T
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1528-36. PubMed ID: 17162244
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HCC in older patients.
    Carr BI; Pancoska P; Branch RA
    Dig Dis Sci; 2010 Dec; 55(12):3584-90. PubMed ID: 20238246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Small hepatocellular carcinoma in Chinese patients.
    Carr BI; Lu SN; Pancoska P
    Hepatogastroenterology; 2011; 58(109):1334-42. PubMed ID: 21937405
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
    Kwak HW; Park JW; Nam BH; Yu A; Woo SM; Kim TH; Kim SH; Koh YH; Kim HB; Park SJ; Lee WJ; Hong EK; Kim CM
    J Gastroenterol Hepatol; 2014 Apr; 29(4):820-9. PubMed ID: 24325272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatic function testing.
    Burke MD
    Postgrad Med; 1978 Sep; 64(3):177-82, 185. PubMed ID: 81485
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center.
    Huo TI; Huang YH; Lui WY; Wu JC; Lee PC; Chang FY; Lee SD
    Oncol Rep; 2004 Feb; 11(2):543-50. PubMed ID: 14719097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elevated serum vitamin B(12) levels in association with tumor markers as the prognostic factors predictive for poor survival in patients with hepatocellular carcinoma.
    Lin CY; Kuo CS; Lu CL; Wu MY; Huang RF
    Nutr Cancer; 2010; 62(2):190-7. PubMed ID: 20099193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Hiraoka A; Horiike N; Yamashita Y; Koizumi Y; Doi H; Yamamoto Y; Ichikawa S; Hasebe A; Yano M; Miyamoto Y; Ninomiya T; Ootani H; Takamura K; Kawasaki H; Otomi Y; Kogame M; Sogabe I; Ishimaru Y; Kashihara K; Miyagawa M; Hirooka M; Hiasa Y; Matsuura B; Michitaka K; Onji M
    Hepatogastroenterology; 2009; 56(89):213-7. PubMed ID: 19453060
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.
    Giannini EG; Marenco S; Borgonovo G; Savarino V; Farinati F; Del Poggio P; Rapaccini GL; Anna Di Nolfo M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
    Hepatology; 2012 Oct; 56(4):1371-9. PubMed ID: 22535689
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Prognosis of hepatocellular carcinoma: a study of 832 cases].
    Yan T; Zhao JJ; Bi XY; Zhao H; Huang Z; Li ZY; Zhou JG; Li Y; Li C; Cai JQ; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):54-8. PubMed ID: 23648302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment and prognostic factors in patients with hepatocellular carcinoma.
    Martins A; Cortez-Pinto H; Marques-Vidal P; Mendes N; Silva S; Fatela N; Glória H; Marinho R; Távora I; Ramalho F; de Moura MC
    Liver Int; 2006 Aug; 26(6):680-7. PubMed ID: 16842324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma.
    Omagari K; Honda S; Kadokawa Y; Isomoto H; Takeshima F; Hayashida K; Mizuta Y; Murata I; Kohno S
    J Gastroenterol Hepatol; 2004 Jul; 19(7):805-11. PubMed ID: 15209629
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment outcome of transcatheter arterial chemoinfusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma (TNM stage IVa).
    Ahn SH; Han KH; Park JY; Youn YH; Moon CM; Lee KS; Chon CY; Moon YM; Lee DY; Lee JT
    Yonsei Med J; 2004 Oct; 45(5):847-58. PubMed ID: 15515195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series.
    Sapisochin G; Goldaracena N; Astete S; Laurence JM; Davidson D; Rafael E; Castells L; Sandroussi C; Bilbao I; Dopazo C; Grant DR; Lázaro JL; Caralt M; Ghanekar A; McGilvray ID; Lilly L; Cattral MS; Selzner M; Charco R; Greig PD
    Ann Surg Oncol; 2015 Jul; 22(7):2286-94. PubMed ID: 25472651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lipoprotein (a) behaviour in patients with hepatocellular carcinoma.
    Motta M; Giugno I; Ruello P; Pistone G; Di Fazio I; Malaguarnera M
    Minerva Med; 2001 Oct; 92(5):301-5. PubMed ID: 11675573
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels.
    Nakazawa T; Adachi S; Kitano M; Isobe Y; Kokubu S; Hidaka H; Ono K; Okuwaki Y; Watanabe M; Shibuya A; Saigenji K
    Oncology; 2007; 73(1-2):90-7. PubMed ID: 18337620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
    Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
    Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.